CODX Stock Overview A molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Co-Diagnostics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Co-Diagnostics Historical stock prices Current Share Price US$0.83 52 Week High US$2.23 52 Week Low US$0.67 Beta -0.85 1 Month Change 2.47% 3 Month Change -35.15% 1 Year Change -40.71% 3 Year Change -90.63% 5 Year Change -23.84% Change since IPO -85.71%
Recent News & Updates
New minor risk - Share price stability Jan 06
Chairman & CEO exercised options and sold US$50k worth of stock Nov 27
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 10
Co-Diagnostics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 26
Consensus revenue estimates increase by 143% Aug 15
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 11 See more updates
New minor risk - Share price stability Jan 06
Chairman & CEO exercised options and sold US$50k worth of stock Nov 27
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 10
Co-Diagnostics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 26
Consensus revenue estimates increase by 143% Aug 15
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 11
Co-Diagnostics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 25
Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024 Jul 17
Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform Jun 15
Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation Jun 14
New minor risk - Share price stability Jun 06
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 13
New minor risk - Shareholder dilution May 12
Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 27
Co-Diagnostics, Inc. Appoints Executive Appointments Apr 04
Full year 2023 earnings released Mar 16
New major risk - Revenue and earnings growth Mar 15
Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024 Mar 01
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro Dec 27
Chairman exercised options and sold US$58k worth of stock Nov 29
Consensus revenue estimates increase by 474% Nov 16
Price target increased by 50% to US$3.00 Nov 15
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 11
Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 27
Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer Aug 30
Consensus revenue estimates fall by 43% Aug 17
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 13
Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023 Jul 23
Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program Jul 14
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14% May 18
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 13
Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023 May 06
A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX) Apr 14
Consensus revenue estimates fall by 83% Mar 23
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 17
Investor sentiment improves as stock rises 16% Jan 31
Chairman exercised options and sold US$111k worth of stock Nov 25
Consensus revenue estimates fall by 14% Nov 17
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 16
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 12 Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer Nov 02
Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 28
Investor sentiment improved over the past week Oct 04
Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers Sep 20
Co-Diagnostics: Hold Thesis Remains Well Intact Sep 07
Investor sentiment deteriorated over the past week Aug 18
Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc Aug 17
Price target decreased to US$15.33 Aug 13
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 12
Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes Aug 11
Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 03
Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022 Jul 21
Co-Diagnostics spikes on shipments of monkeypox test Jul 11
Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX) Jul 06
Investor sentiment improved over the past week Jul 05
Now 20% undervalued after recent price drop Jun 27
Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant Jun 21
Now 24% undervalued after recent price drop May 31
Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus May 27
Chairman exercised options and sold US$59k worth of stock May 26
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 13
Investor sentiment deteriorated over the past week May 11
Price target decreased to US$19.33 Apr 27
High number of new and inexperienced directors Apr 27
Investor sentiment deteriorated over the past week Apr 22
Co-Diagnostics: Where's Eikon? Apr 03
High number of new and inexperienced directors Apr 02
Consensus EPS estimates increase by 36% Mar 31
Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate Mar 28
Investor sentiment improved over the past week Mar 17
Investor sentiment deteriorated over the past week Feb 23
Co-Diagnostics: Swinging For The Fences Jan 24
Investor sentiment deteriorated over the past week Jan 21 Co-Diagnostics, Inc. (NasdaqCM:CODX) completed the acquisition of Advanced Conceptions, Inc.
Price target decreased to US$19.33 Dec 30
Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist? Dec 28
Co-Diagnostics, Inc. (NasdaqCM:CODX) entered into an Agreement and Plan of Merger to acquire Idaho Molecular Inc. Dec 24
Investor sentiment improved over the past week Dec 23
Chairman exercised options and sold US$131k worth of stock Nov 30
Third quarter 2021 earnings released: EPS US$0.40 (vs US$0.56 in 3Q 2020) Nov 12
Co-Diagnostics, Inc. to Introduce at Home/Point of Care Device at AACC on Sept 28 Sep 29
Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy Sep 09
Why Co-Diagnostics Is A Solid Covid-19 Play Aug 19
Consensus forecasts updated Aug 19
Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too Aug 14
Second quarter 2021 earnings released: EPS US$0.34 (vs US$0.54 in 2Q 2020) Aug 13
Co-Diagnostics, Inc. Provides Earnings Guidance for the Third Quarter 2021 Aug 13
Investor sentiment improved over the past week Jul 22 Co-Diagnostics, Inc.(NasdaqCM:CODX) dropped from Russell 3000E Index Shareholder Returns CODX US Medical Equipment US Market 7D 6.4% 2.0% -0.5% 1Y -40.7% 9.8% 23.2%
See full shareholder returns
Return vs Market: CODX underperformed the US Market which returned 23.2% over the past year.
Price Volatility Is CODX's price volatile compared to industry and market? CODX volatility CODX Average Weekly Movement 12.0% Medical Equipment Industry Average Movement 8.2% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.2%
Stable Share Price: CODX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CODX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
Show more Co-Diagnostics, Inc. Fundamentals Summary How do Co-Diagnostics's earnings and revenue compare to its market cap? CODX fundamental statistics Market cap US$24.76m Earnings (TTM ) -US$41.28m Revenue (TTM ) US$7.32m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CODX income statement (TTM ) Revenue US$7.32m Cost of Revenue US$3.71m Gross Profit US$3.61m Other Expenses US$44.89m Earnings -US$41.28m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.29 Gross Margin 49.30% Net Profit Margin -563.91% Debt/Equity Ratio 0%
How did CODX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 01:12 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Co-Diagnostics, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yi Chen H.C. Wainwright & Co. James Sidoti Sidoti & Company, LLC
Show 0 more analysts 
